

# Tuberculosis profile: Fiji

Population 2021: 0.92 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	610 (470-780)	66 (51-84)
HIV-positive TB incidence	50 (30-75)	5.4 (3.2-8.1)
MDR/RR-TB incidence**	10 (3-17)	1.1 (0.29-1.8)
HIV-negative TB mortality	41 (40-41)	4.4 (4.3-4.5)
HIV-positive TB mortality	8 (5-12)	0.88 (0.51-1.3)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	1.1% (0.46-2.1)
Previously treated cases	8.8% (2.2-20)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	56% (44-73)
TB patients facing catastrophic total costs, 2017	40% (33-46)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	8% (6-10)

## TB case notifications, 2021

Total new and relapse	342
- % tested with rapid diagnostics at time of diagnosis	40%
- % with known HIV status	>100%
- % pulmonary	78%
- % bacteriologically confirmed ^	51%
- % children aged 0-14 years	15%
- % women (aged ≥15 years)	32%
- % men (aged ≥15 years)	53%
Total cases notified	372

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	28	8.1%
- on antiretroviral therapy	28	100%

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	96%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	4
Patients started on treatment - MDR/RR-TB ^^	3
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	54%	443
Previously treated cases, excluding relapse, registered in 2020	60%	5
HIV-positive TB cases registered in 2020	80%	5
MDR/RR-TB cases started on second-line treatment in 2019	100%	1
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0


## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)


## Funding for TB

Funding for TB, 2021 (US\$ millions)	1
- % domestic funding	96%
- % international funding	4.4%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021 (Number)



## Cases attributable to five risk factors, 2021 (Number)



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

---

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)